Policy & Regulation
Evotec enters into global collaboration with Galapagos
12 February 2019 -

Germany-based Evotec has entered into global collaboration with Galapagos, a Belgo-Dutch pharmaceutical research company.

It was reported yesterday that the collaboration is aimed at a novel target for fibrosis and other indications. It concerns a small molecule programme, presently in pre-clinical development for the treatment of fibrotic diseases of the liver and other organs. The target has been identified and validated using Evotec's proprietary platforms for fibrotic diseases and non-alcoholic steatohepatitis (NASH). Evotec used its in-house assay development and drug screening capabilities to identify small molecule modulators against the target, which remains unrevealed. In exchange for global commercialisation rights to Galapagos, Evotec receives an upfront payment and is eligible for potential milestone and royalty payments. Galapagos will be responsible for all further development of the programme. Galapagos will also have access to specific screening formats at Evotec to support the final pre-clinical development.

Dr Cord Dohrmann, chief scientific officer for Evotec, said, 'We are delighted to be working with Galapagos on this innovative project in an area of high unmet medical need. The team at Galapagos share our focus on novel, first-in-class therapeutic candidates and we are glad to be part of their portfolio building.'